膵臓がん患者由来濃縮腹水中IFN-γ及びIL-12の膵臓がん細胞に対する増殖抑制効果

DOI Web Site Web Site PubMed 参考文献62件

書誌事項

タイトル別名
  • IFN-γ and IL-12 from Concentrated Ascites in Patients with Pancreatic Cancer Exerts Growth Inhibitory Effects against Pancreatic Cancer Cells
  • スイゾウ ガン カンジャ ユライ ノウシュク フクスイチュウ IFN-gオヨビ IL-12 ノ スイゾウ ガン サイボウ ニ タイスル ゾウショク ヨクセイ コウカ

この論文をさがす

抄録

<p>Patients with pancreatic cancer (PC) often suffer from refractory ascites associated with peritoneal metastasis. This severely impairs activities of daily living and leads to an unfavorable prognosis. Cell-free and concentrated ascites reinfusion therapy (CART) has attracted attention as a promising therapy for relieving the symptoms of malignant ascites. Accumulating evidence suggests that malignant ascites contains a variety of soluble factors, such as cytokines, that can be beneficial or detrimental in the prognosis of patients with refractory ascites. However, the expression profiles of these cytokines in the ascites before and after CART remain unknown. In this study, we used a comprehensive cytokine array to measure the expression levels of 102 cytokines in ascites derived from patients with PC before and after CART. The assay results revealed that the concentrations of several cytokines exacerbating tumor angiogenesis and tumor-suppressive interferon-gamma (IFN-γ) and interleukin-12 (IL-12) were higher in ascites after CART than before CART. Interestingly, growth of KP-2 human PC cells following exposure to ascites after CART decreased considerably compared to that before CART. Concomitant treatment of neutralizing antibodies against IFN-γ or IL-12 with ascites after CART restored the growth of KP-2 cells to the control level. These findings indicate that IFN-γ and IL-12 in ascites after CART may contribute to the inhibited growth of PC cells, highlighting their potential as biomarkers for assessing the clinical efficacy of CART procedures in patients with PC.</p>

収録刊行物

  • 薬学雑誌

    薬学雑誌 142 (12), 1409-1417, 2022-12-01

    公益社団法人 日本薬学会

参考文献 (62)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ